# Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma

> **NCT00109798** · NA · WITHDRAWN · sponsor: **The Methodist Hospital Research Institute**

## Conditions studied

- Central Nervous System Tumors
- Lymphoma

## Interventions

- **DRUG:** temozolomide
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00109798
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-03
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sub-Investigator reloacted to another institution
- **Last updated:** 2017-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109798, "Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00109798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*